Abacus Planning Group, Inc. Biogen Inc. Transaction History

Abacus Planning Group, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 18, 2022	SELL	$223.92 - $287.77 $209,141 - $268,777	-934 Closed	0 $0
Q3 2021 Oct 19, 2021	BUY	$282.99 - $369.05 $41,599 - $54,250	147 Added 18.68%	934 $264,000
Q1 2021 Apr 27, 2021	SELL	$242.95 - $284.63 $8,260 - $9,677	-34 Reduced 4.14%	787 $220,000
Q4 2020 Feb 01, 2021	SELL	$236.26 - $355.63 $94,504 - $142,252	-400 Reduced 32.76%	821 $201,000
Q2 2020 Aug 11, 2020	SELL	$258.66 - $342.55 $91,306 - $120,920	-353 Reduced 22.43%	1,221 $327,000
Q1 2020 Apr 30, 2020	BUY	$268.85 - $341.04 $80,655 - $102,312	300 Added 23.55%	1,574 $498,000
Q3 2019 Nov 01, 2019	BUY	$217.44 - $243.88 $277,018 - $310,703	1,274 New	1,274 $297,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Abacus Planning Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Abacus Planning Group, Inc. with notifications on news.